NeuropacevsThermo Fisher Scientific

NPCE and TMO stock compared: price, dividend, valuation and results, from SEC filings.

NPCE

Neuropace, Inc.

$7.56

Value $255M

-37.10%
NPCE's page

TMO

Thermo Fisher Scientific Inc

$700.22

Value $260B

+0.11%
TMO's page

Neuropace (NPCE) has a market value of $255M and Thermo Fisher Scientific (TMO) $260B. Over the last year, with dividends, NPCE moved -44.0% and TMO +19.5%. Dividend yield: NPCE none, TMO 0.26%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    NPCE$255M

    TMO$260B

    TMO is 1,022 times NPCE

  • Revenue, 12 months

    NPCE$103M

    TMO$47.4B

    TMO is 461 times NPCE

  • Net income, 12 months

    NPCE-$19M

    TMO$7.1B

  • Operating margin

    NPCE-11.5%

    TMO17.9%

    29.4 points apart

  • ROIC

    NPCE-12.6%

    TMO8.2%

    20.8 points apart

  • P/E

    NPCE–

    TMO36.8

  • Dividend yield

    NPCE0.0%

    TMO0.3%

    0.3 points apart

  • 5-year return

    NPCE-46.0%

    TMO+11.8%

    57.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

NPCE-46.0%

TMO+11.8%

5010020222023202420252026
Returns by period
PeriodNPCEWith dividendsTMOWith dividends
1 year since November 12, 2025-44.0%Price -44.0%+19.5%Price +19.1%
3 years since November 13, 2023-11.0%-3.8% a yearPrice -11.0%+58.8%+16.7% a yearPrice +57.3%
5 years since November 12, 2021-46.0%-11.6% a yearPrice -46.0%+11.8%+2.3% a yearPrice +10.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

NPCENeuropaceTMOThermo Fisher Scientific

Valuation

NPCETMO
Valuation
Price$7.56$700.22
Market value$255M$260B
Enterprise value (EV)–$295B
P/E–36.8
P/E, 5-year median–32.7
P/B22.24.8
EV/EBIT–34.9
Free cash flow yield–2.9%

Results and growth

NPCETMO
Results and growth
Revenue, 12 months$103M$47.4B
Net income, 12 months-$19M$7.1B
Free cash flow, 12 months-$12M$7.6B
Earnings per share, 12 months-$0.56$18.96
Revenue growth, year on year25.1%3.9%
Revenue growth a year, past+19.4%over 5 years+6.7%over 5 years
EPS growth a year, past–+2.1%over 5 years

Margins and returns on capital

NPCETMO
Margins and returns on capital
Gross margin78.9%–
Operating margin-11.5%17.9%
Net margin-18.4%14.9%
ROIC-12.6%8.2%
ROE-125.5%13.4%

Balance sheet

NPCETMO
Balance sheet
Cash$49M$6.1B
Total debt–$41.4B
Net debt / EBITDA–3.7
Interest cover-1.9×5.5×

Dividends and buybacks

NPCETMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield19.5%1.2%
Shareholder yield19.5%1.4%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: NPCE or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Neuropace or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($260B) is about 1,022.0 times Neuropace ($255M), at today's prices.

How did NPCE and TMO stock do over the last 5 years?

Since November 12, 2021, NPCE's price moved -46.0% and TMO's +10.2%. With dividends: NPCE -46.0% (-11.6% a year), TMO +11.8% (+2.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, NPCE or TMO?

The dividend yield at today's price is none for Neuropace and 0.26% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

Which has the higher profit margins, Neuropace or Thermo Fisher Scientific?

Over the last twelve months, the net margin was -18.4% for Neuropace and 14.9% for Thermo Fisher Scientific, and the operating margin -11.5% and 17.9%. Revenue was $103M and $47.4B.

Which is the better investment, Neuropace or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.